Data is generated through a variety of ways and is growing rapidly in size and complexity. This data is important to advancing innovation and enabling better healthcare decisions. However, collected data is generally unstructured and unorganized limiting its value to pharma.
RetinAI develops solutions to harmonize data and gain powerful insights through AI. Our solutions enable target-based research and clinical studies, ultimately bringer innovative products to patients, faster.
RetinAI’s Discovery Unity platform aggregates data to generate insights on disease biomarkers and outcomes, with predictive analytics for analyzing cause and effect.
Researchers can quickly organize outcomes by patient subgroups. Research is target-based and accelerated to improve clinical development success.
RetinAI Discovery is supporting large-scale clinical studies in EU and North America, with a go-to platform for data collection, clinical and imaging data, and enhanced endpoint analysis via AI.
Pharma can centralize their clinical study data & RWE for real time access and coordination of analysis and grading with reading centers and external reviewers.
RetinAI Discovery’s certified AI can be used for the development and validation of clinical decision support tools or AI-companion diagnostics (CDx).
These products can help stratify patients, monitor treatment responses or personalize dosing based on biomarker profiles. Benefits can support patients and payers for optimizing treatments.
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.